Genmab 대차 대조표 상태 Genmab 의 총 주주 지분은 DKK31.9B 이고 총 부채는 DKK0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 DKK39.7B 및 DKK7.7B 입니다. Genmab 의 EBIT는 DKK6.6B 이며 이자보상배율은 -6.6 입니다. DKK17.3B 의 현금 및 단기 투자금을 보유하고 있습니다.
주요 정보 이자 보상 비율 -6.6x 현금 DKK 17.32b 주식 DKK 31.92b 총 부채 DKK 7.74b 총 자산 DKK 39.66b
최근 재무 상태 업데이트
모든 업데이트 표시
Third quarter 2024 earnings released: EPS: kr.19.94 (vs kr.32.60 in 3Q 2023) Nov 08
Genmab Announces New Data from the Phase 1/2 Study Of Rinatabart Sesutecan (Rina-S), an Investigational Folate Receptor-Alpha (FRa)-Targeted, Topo1 Antibody-Drug Conjugate Sep 16
Genmab A/S Receives Second European Commission Approval for the Treatment of Adults with Relapsed/Refractory Follicular Lymphoma Aug 20
Genmab A/S Announces Executive Changes Aug 16
Second quarter 2024 earnings released: EPS: kr.21.85 (vs kr.20.46 in 2Q 2023) Aug 11
Genmab A/S Takes Full Control of Acasunlimab Development Program Aug 06
Genmab A/S Announces That the U.S. Food and Drug Administration Approved Epkinly® (Epcoritamab-Bysp) for the Treatment of Adults with Relapsed or Refractory Follicular Lymphoma After Two or More Lines of Systemic EPKINLY Jun 27
Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma Jun 05 Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc. May 22
Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress May 15
First quarter 2024 earnings released: EPS: kr.20.29 (vs kr.3.46 in 1Q 2023) May 03 Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer Apr 30
Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion. Apr 05
Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion. Apr 03
Genmab A/S Announces Executive Changes Mar 14
Executive VP & CFO recently sold €2.9m worth of stock Mar 03 Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma Feb 27
Full year 2023 earnings released: EPS: kr.66.64 (vs kr.84.45 in FY 2022) Feb 16 Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®? Feb 03
Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc Jan 23 Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application Jan 10
Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma Dec 11
Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma Nov 29
Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma Nov 28
Genmab A/S Revises Earnings Guidance for the Year 2023 Nov 08
New minor risk - Profit margin trend Nov 08
Third quarter 2023 earnings released: EPS: kr.32.60 (vs kr.39.55 in 3Q 2022) Nov 08
Genmab A/S, Annual General Meeting, Mar 13, 2024 Oct 28 Genmab A/S to Report Q1, 2024 Results on May 02, 2024 Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial Oct 24
New minor risk - Share price stability Oct 20
Investor sentiment deteriorates as stock falls 17% Oct 18 Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy Sep 05
Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022) Aug 04
Second quarter 2023 earnings released: EPS: kr.20.80 (vs kr.28.87 in 2Q 2022) Aug 04
Genmab A/S Revises Earning Guidance for the Year 2023 Jul 29
Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma Jul 23 AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL) Jun 28
Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’ Jun 23
Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023 Jun 09
Co-Founder recently sold €7.8m worth of stock Jun 02
U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma May 20 Genmab A/S Provides Earnings Guidance for 2023 May 11
First quarter 2023 earnings released: EPS: kr.3.46 (vs kr.7.10 in 1Q 2022) May 11
Independent Chairman of the Board recently bought €107k worth of stock Apr 08
Full year 2022 earnings released: EPS: kr.84.45 (vs kr.46.00 in FY 2021) Feb 24
Insufficient new directors Feb 01
Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Dec 22
Co-Founder recently sold €7.7m worth of stock Dec 16
Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting Dec 13 Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023
Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl) Nov 22
Third quarter 2022 earnings released: EPS: kr.39.55 (vs kr.13.61 in 3Q 2021) Nov 10 Genmab Provides Earnings Guidance for Year 2022
Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration Oct 29
Second quarter 2022 earnings released: EPS: kr.28.87 (vs kr.4.68 in 2Q 2021) Aug 11
Genmab A/S Revises Earnings Guidance for the Year 2022 Aug 09
Investor sentiment improved over the past week Jul 06
Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma Jul 01
Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium Jun 13
Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting Jun 07
재무 상태 분석
단기부채: GE9 의 단기 자산 ( DKK23.7B )이 단기 부채 ( DKK4.6B ).
장기 부채: GE9 의 단기 자산( DKK23.7B )이 장기 부채 ( DKK3.2B ).
부채 대 자본 내역 및 분석
부채 감소: GE9 지난 5년간 부채가 없습니다.
부채 범위: GE9 은 부채가 없으므로 영업현금흐름 으로 충당할 필요가 없습니다.
이자 보장: GE9 에는 부채가 없으므로 이자 지불 에 대한 보장은 문제가 되지 않습니다.
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":true,"variant":{"name":"control","enabled":true,"feature_enabled":true,"featureEnabled":true},"flagsReady":true,"flagsError":null}